These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 8361756)

  • 1. Transforming activity and tissue tropism of hybrid retroviral genomes containing portions of the v-abl and v-src oncogenes.
    Hevezi P; Alin K; Goff SP
    Oncogene; 1993 Sep; 8(9):2413-23. PubMed ID: 8361756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro transformation of murine pro-B and pre-B cells by v-mpl, a truncated form of a cytokine receptor.
    Fichelson S; Vigon I; Dusanter I; Charon M; Velu T; Baillou C; Gisselbrecht S; Lemoine FM
    J Immunol; 1995 Feb; 154(4):1577-86. PubMed ID: 7836743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutation of a phenylalanine conserved in SH3-containing tyrosine kinases activates the transforming ability of c-Abl.
    Jackson PK; Paskind M; Baltimore D
    Oncogene; 1993 Jul; 8(7):1943-56. PubMed ID: 8510937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction between Raf and Myc oncogenes in transformation in vivo and in vitro.
    Cleveland JL; Jansen HW; Bister K; Fredrickson TN; Morse HC; Ihle JN; Rapp UR
    J Cell Biochem; 1986; 30(3):195-218. PubMed ID: 3084503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone marrow-transforming activity of linker insertion mutants of Abelson murine leukemia virus.
    Hevezi P; Alin K; Rees-Jones R; Goff SP
    Oncogene; 1992 Nov; 7(11):2323-8. PubMed ID: 1437154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A retrovirus that expresses v-abl and c-myc oncogenes rapidly induces plasmacytomas.
    Largaespada DA; Kaehler DA; Mishak H; Weissinger E; Potter M; Mushinski JF; Risser R
    Oncogene; 1992 Apr; 7(4):811-9. PubMed ID: 1565479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Morphological transformation, tumorigenicity and src-specific cytotoxic T-lymphocyte-mediated tumor immunity induced by murine 3T3 cells expressing src oncogenes encoding novel non-myristylated N-terminal domains.
    Gelman IH; Khan S; Hanafusa H
    Oncogene; 1993 Nov; 8(11):2995-3004. PubMed ID: 7692370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells.
    Gross AW; Ren R
    Oncogene; 2000 Dec; 19(54):6286-96. PubMed ID: 11175343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arrested development: understanding v-abl.
    Kerr LD
    Bioessays; 1994 Jul; 16(7):453-5. PubMed ID: 7945272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of chimeric Gag-Arg/Abl molecules indicates a distinct negative regulatory role for the Arg C-terminal domain.
    Mysliwiec T; Perego R; Kruh GD
    Oncogene; 1996 Feb; 12(3):631-40. PubMed ID: 8637720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two novel variants of the v-src oncogene isolated from low and high metastatic RSV-transformed hamster cells.
    Tatosyan A; Yatsula B; Shtutman M; Moinova E; Kaverina I; Musatkina E; Leskov K; Mizenina O; Zueva E; Calothy G; Dezélée P
    Virology; 1996 Feb; 216(2):347-56. PubMed ID: 8607264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transforming pathways activated by the v-Abl tyrosine kinase.
    Shore SK; Tantravahi RV; Reddy EP
    Oncogene; 2002 Dec; 21(56):8568-76. PubMed ID: 12476303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure and function of the Abelson murine leukemia virus transforming gene.
    Wang JY; Prywes R; Baltimore D
    Prog Clin Biol Res; 1983; 119():57-63. PubMed ID: 6306691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single point mutations in the SH2 domain impair the transforming potential of vav and fail to activate proto-vav.
    Katzav S
    Oncogene; 1993 Jul; 8(7):1757-63. PubMed ID: 8510922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of v-Abl transformation by p53 and p19ARF.
    Cong F; Zou X; Hinrichs K; Calame K; Goff SP
    Oncogene; 1999 Dec; 18(54):7731-9. PubMed ID: 10618713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel mutation within the kinase domain of v-abl gene responsible for temperature-sensitive colony-forming ability in soft agar.
    Soma T; Tsukada S; Oka Y; Kishimoto T; Sugiyama H
    Virology; 1993 Apr; 193(2):967-70. PubMed ID: 8460498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ETV6-NTRK3 gene fusion encodes a chimeric protein tyrosine kinase that transforms NIH3T3 cells.
    Wai DH; Knezevich SR; Lucas T; Jansen B; Kay RJ; Sorensen PH
    Oncogene; 2000 Feb; 19(7):906-15. PubMed ID: 10702799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.
    Buchdunger E; Zimmermann J; Mett H; Meyer T; Müller M; Druker BJ; Lydon NB
    Cancer Res; 1996 Jan; 56(1):100-4. PubMed ID: 8548747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced phosphotyrosine binding by the v-Src SH2 domain is compatible with wild-type transformation.
    Tian M; Martin GS
    Oncogene; 1996 Feb; 12(4):727-34. PubMed ID: 8632894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of growth factor-independence and GM-CSF secretion by the v-src oncogene in murine myeloid cells does not require membrane association of pp60v-src.
    Ostermeyer AG; Anderson SM
    Exp Hematol; 1996 Feb; 24(2):176-84. PubMed ID: 8641339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.